{"id":327733,"date":"2021-10-08T02:00:00","date_gmt":"2021-10-08T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/secukinumab-ready-to-use-300-mg-injection-convinces\/"},"modified":"2021-10-08T02:00:00","modified_gmt":"2021-10-08T00:00:00","slug":"secukinumab-ready-to-use-300-mg-injection-convinces","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/secukinumab-ready-to-use-300-mg-injection-convinces\/","title":{"rendered":"Secukinumab ready-to-use 300 mg injection convinces"},"content":{"rendered":"

The EMA-approved new route of administration for the IL-17A inhibitor allows the recommended dosage to be administered in a single injection. Data analyses of the pivotal phase IIIb MATURE study were presented at the World Psoriasis & Psoriatic Arthritis Conference 2021. Among other things, these demonstrate a high level of patient satisfaction.<\/strong><\/p>\n

<\/p>\n

Secukinumab is a monoclonal antibody that targets interleukin (IL)-17A. The clinical evidence of this biologic in the treatment of patients with plaque psoriasis and psoriatic arthritis is extensively documented [1,2]. The recommended dose of secukinumab (Cosentyx\u00ae) is 300 mg as a subcutaneous injection [3]. In addition to the 150 mg application form, Cosentyx\u00ae has been available in the EU as a 300 mg ready-to-use pen since mid-February 2021 [4].<\/p>\n

MATURE study: improvements in various outcome parameters.<\/h2>\n

122 psoriasis patients were randomized to three study arms [5]: Secukinumab 300 mg 2 mL autoinjector (n=41), Secukinumab 300 mg 2\u00d7 1 mL pre-filled syringe\/PFS* (n=41), or placebo (n=40). At week 12, both co-primary endpoints of the study were met, demonstrating that treatment with secukinumab 300 mg 2 mL AI and 2\u00d7 1 mL PFS resulted in superior PASI75 response rates (95.1% and 83.2%, respectively), as well as lesion-free or nearly lesion-free skin according to IGA (75.6% and 68.1%, respectively) vs. placebo (PASI75, 10.0%; IGA, 7.6%; p<0,0001). The proportion of patients achieving DLQI 0\/1 at week 12 was similar in the secukinumab 300 mg groups (2 mL AI [71,1%] and 2\u00d7 1 mL PFS [72,5%]); on placebo, this proportion was 8.1%.<\/p>\n

* PFS=pre-filled syringes<\/span><\/em><\/p>\n

 <\/p>\n

Neither needlestick injuries in critical localizations nor immediate-type allergies were observed. Patient satisfaction was assessed using the Self-Injection Assessment Questionnaire (SIAQ) and other instruments. In the secukinumab 300 mg 2 mL autoinjector group, the proportion of patients who reported being “very satisfied” or “satisfied” increased from 31.6% (pre-SIAQ) to 78.3% (post-SIAQ) after the first injection and continued to increase to 92.1% at week 12.<\/p>\n

Conclusion<\/h2>\n

In summary, the secukinumab 300 mg 2 mL autoinjector route of administration was convincing in terms of both rapid response, high efficacy, and quality of life, as well as  high patient satisfaction scores and a favorable safety profile. No new or unexpected safety signals appeared in the present study.<\/p>\n

Source: Novartis<\/em>
\n <\/p>\n

Literature:<\/p>\n

    \n
  1. Blauvelt A, et al: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1): 60-9 e9.<\/li>\n
  2. Strober BE, et al: No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2): e105-e7.<\/li>\n
  3. Drug Information, www.swissmedicinfo.ch (last accessed Aug. 12, 2021).<\/li>\n
  4. “Perspectives on Dermatology. Secukinumab: 300 mg Prefilled Pen – High Patient Satisfaction,” Supplement, Dtsch Arztebl 2021; 118(24).<\/li>\n
  5. Browning J, et al: Secukinumab 300 mg in 2 mL autoinjector for treatment of plaque psoriasis: quality of life, usability, satisfaction, safety and tolerability results from the randomised, double-blind MATURE study, Poster abstracts, P77, World Psoriasis & Psoriatic Arthritis Conference, Stockholm, 30 Jun-03 Jul 2021.<\/li>\n<\/ol>\n

     <\/p>\n

    DERMATOLOGY PRACTICE 2021; 31(4): 32<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    The EMA-approved new route of administration for the IL-17A inhibitor allows the recommended dosage to be administered in a single injection. Data analyses of the pivotal phase IIIb MATURE study…<\/p>\n","protected":false},"author":7,"featured_media":110836,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Plaque psoriasis ","footnotes":""},"category":[11331,11340,11530,11480,11548,11503],"tags":[12923,14032],"powerkit_post_featured":[],"class_list":["post-327733","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergology-and-clinical-immunology","category-dermatology-and-venereology","category-market-medicine","category-rheumatology","category-rx-en","category-studies","tag-psoriasis-en","tag-psoriasis-en-2","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-30 16:47:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":327742,"slug":"le-secukinumab-pret-a-lemploi-en-injection-de-300-mg-est-convaincant","post_title":"Le s\u00e9cukinumab pr\u00eat \u00e0 l'emploi en injection de 300 mg est convaincant","href":"https:\/\/medizinonline.com\/fr\/le-secukinumab-pret-a-lemploi-en-injection-de-300-mg-est-convaincant\/"},"it_IT":{"locale":"it_IT","id":327745,"slug":"secukinumab-penna-prefabbricata-come-iniezione-da-300-mg-convincente","post_title":"Secukinumab penna prefabbricata come iniezione da 300 mg convincente","href":"https:\/\/medizinonline.com\/it\/secukinumab-penna-prefabbricata-come-iniezione-da-300-mg-convincente\/"},"pt_PT":{"locale":"pt_PT","id":327750,"slug":"caneta-pre-fabricada-secukinumab-como-300-mg-de-injeccao-convincente","post_title":"Caneta pr\u00e9-fabricada Secukinumab como 300 mg de injec\u00e7\u00e3o convincente","href":"https:\/\/medizinonline.com\/pt-pt\/caneta-pre-fabricada-secukinumab-como-300-mg-de-injeccao-convincente\/"},"es_ES":{"locale":"es_ES","id":327756,"slug":"secukinumab-pluma-prefabricada-como-inyeccion-de-300-mg-convincente","post_title":"Secukinumab pluma prefabricada como inyecci\u00f3n de 300 mg convincente","href":"https:\/\/medizinonline.com\/es\/secukinumab-pluma-prefabricada-como-inyeccion-de-300-mg-convincente\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/327733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=327733"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/327733\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/110836"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=327733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=327733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=327733"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=327733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}